Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 102Breast Neoplasms 10Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 6Triple Negative Breast Neoplasms 5Castration-resistant Prostate Cancer 4Urinary Bladder Neoplasms 3Pancreatic Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Prostate Cancer Metastatic 2Prostate Adenocarcinoma 2Ovarian Neoplasms 2Neoplasms 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2Metastatic Castration-Resistant Prostate Cancer 2Metastatic Castration Resistant Prostate Cancer 2Castration Resistant Metastatic Prostate Cancer 2Carcinoma, Hepatocellular 2Adenocarcinoma of the Prostate 2Adenocarcinoma 2Uterine Cervical Neoplasms 1Urinary Bladder Diseases 1Urethral Neoplasms 1Ureteral Neoplasms 1Ureteral Diseases 1Thrombocytosis 1Stomach Neoplasms 1Solid Tumor 1Salivary Cancer 1Recurrent Endometrial Endometrioid Adenocarcinoma 1

Interventions

enzalutamide 2sapanisertib 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Metastatic Castration-Resistant Prostate Cancer × enzalutamide × Clear all
NCT04419402 2024-02-07

ENZA-p

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Phase 2 Unknown
162 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02125357 2020-08-07

Sequencing Abiraterone and Enzalutamide in mCRPC

British Columbia Cancer Agency

Phase 2 Completed
202 enrolled
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡